| |
| |
| Exchange: |
Nasdaq National Market |
| Security
Type: |
Common |
| Shares
Out: |
122,563,000 |
| Market
Cap: |
6.61(B) |
| Last
Volume: |
8,264,325 |
Avg
Vol: |
8,241,969 |
| 52
Week Range: |
$26.88 - $108.06 |
|
| Level
I Sector: |
Health Care |
| Level
II Sector: |
Drugs |
| Level
III Sector: |
Biotechnology |
|
Member Indexes:
|
| |
NASDAQ BIOTECHNOLOGY |
|
NASDAQ COMPOSITE |
| |
NASDAQ NNM COMPOSITE |
|
Rankings:
|
|
| Insider 3 Months : - |
| Insider 6 Months : - |
| Insider 3/6 Months : - |
|
| Guru Rank Number : - |
| Guru Rank Value : - |
| Guru Occurances : - |
|
|
|
|
|
| |
|
Company Profile Cytokinetics is a biopharmaceutical company focused on discovering, developing and commercializing muscle activators and muscle inhibitors as potential treatments for debilitating diseases in which muscle performance is compromised and/or declining. Co.'s clinical-stage drug candidates are: Omecamtiv mecarbil, which is being evaluated for the potential treatment of heart failure; Reldesemtiv, which is being evaluated for treatment in patients with amyotrophic lateral sclerosis; Aficamten, which is an oral, small molecule cardiac myosin inhibitor being evaluated in patients with symptomatic, obstructive hypertrophic cardiomyopathy; and CK-3772271, its second cardiac myosin inhibitor.
|
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
|
3m +/-:
|
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
|
Actions:
|
|
|
| B |
Buy |
| S |
Sell |
| OE |
Option
Exercised |
| A |
Acquired |
| D |
Disposed |
| AB |
Automatic
Buy |
| AS |
Automatic
Sell |
| IO |
Initial
Ownership |
|
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
| |
| |
Summary (Direct Transactions Only)  |
3 Months |
6 Months |
12 Months |
24 Months |
| Total Shares Bought |
0 |
0 |
0 |
0 |
| Total Buy Value |
$0 |
$0 |
$0 |
$0 |
| Total People Bought |
0 |
0 |
0 |
0 |
| Total Buy Transactions |
0 |
0 |
0 |
0 |
| Total Shares Sold |
110,593 |
276,438 |
434,458 |
898,780 |
| Total Sell Value |
$6,689,254 |
$18,972,868 |
$24,231,754 |
$44,996,315 |
| Total People Sold |
7 |
8 |
8 |
12 |
| Total Sell Transactions |
9 |
21 |
39 |
85 |
| End Date |
2024-03-17 |
2023-12-15 |
2023-06-16 |
2022-06-16 |
|
| Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
  Gage L Patrick |
Director |
– • – |
2020-12-15 |
4 |
OE |
$12.96 |
$99,999 |
D/D |
7,716 |
28,520 |
|
- |
|
| Malik Fady Ibraham |
EVP Research & Development |
• – – |
2020-12-10 |
4 |
AS |
$20.13 |
$21,177 |
D/D |
(1,052) |
150,441 |
|
31% |
|
| Lampert Mark N |
See Explanation of Responses |
– – – |
2020-12-09 |
4 |
S |
$18.00 |
$7,757,172 |
D/D |
(430,954) |
463,244 |
|
-24% |
|
| Blum Robert I |
President & CEO |
• • – |
2020-11-23 |
4 |
AS |
$15.73 |
$78,644 |
D/D |
(5,000) |
304,868 |
|
50% |
|
| Blum Robert I |
President & CEO |
• • – |
2020-11-23 |
4 |
OE |
$6.00 |
$30,000 |
D/D |
5,000 |
309,868 |
|
- |
|
| Malik Fady Ibraham |
EVP Research & Development |
• – – |
2020-11-12 |
4 |
AS |
$17.15 |
$21,112 |
D/D |
(1,231) |
150,951 |
|
38% |
|
| Blum Robert I |
President & CEO |
• • – |
2020-11-10 |
4 |
AS |
$16.50 |
$82,488 |
D/D |
(5,000) |
304,868 |
|
40% |
|
| Blum Robert I |
President & CEO |
• • – |
2020-11-10 |
4 |
OE |
$6.00 |
$30,000 |
D/D |
5,000 |
309,868 |
|
- |
|
| Blum Robert I |
President & CEO |
• • – |
2020-10-29 |
4 |
AS |
$15.15 |
$75,773 |
D/D |
(5,000) |
304,868 |
|
31% |
|
| Blum Robert I |
President & CEO |
• • – |
2020-10-29 |
4 |
OE |
$6.00 |
$30,000 |
D/D |
5,000 |
309,868 |
|
- |
|
| Blum Robert I |
President & CEO |
• • – |
2020-10-13 |
4 |
AS |
$15.94 |
$79,686 |
D/D |
(5,000) |
304,868 |
|
20% |
|
| Blum Robert I |
President & CEO |
• • – |
2020-10-13 |
4 |
OE |
$6.00 |
$30,000 |
D/D |
5,000 |
309,868 |
|
- |
|
| Malik Fady Ibraham |
EVP Research & Development |
• – – |
2020-10-08 |
4 |
AS |
$17.45 |
$21,952 |
D/D |
(1,258) |
152,182 |
|
33% |
|
| Parshall B Lynne |
Director |
– • – |
2020-10-05 |
4 |
AS |
$30.00 |
$1,509,330 |
D/D |
(50,311) |
0 |
|
-27% |
|
| Parshall B Lynne |
Director |
– • – |
2020-10-05 |
4 |
OE |
$6.21 |
$363,898 |
D/D |
50,311 |
5,936 |
|
- |
|
| Costa Santo J |
Director |
– • – |
2020-10-05 |
4 |
AS |
$30.00 |
$450,000 |
D/D |
(15,000) |
0 |
|
-27% |
|
| Costa Santo J |
Director |
– • – |
2020-10-05 |
4 |
OE |
$9.45 |
$141,750 |
D/D |
15,000 |
15,000 |
|
- |
|
| Kaye Edward M. Md |
Director |
– • – |
2020-10-05 |
4 |
AS |
$30.00 |
$600,000 |
D/D |
(20,000) |
0 |
|
-27% |
|
| Kaye Edward M. Md |
Director |
– • – |
2020-10-05 |
4 |
OE |
$7.61 |
$152,200 |
D/D |
20,000 |
20,000 |
|
- |
|
| Smith Sandford D |
Director |
– • – |
2020-10-05 |
4 |
AS |
$30.00 |
$178,080 |
D/D |
(5,936) |
0 |
|
-27% |
|
| Smith Sandford D |
Director |
– • – |
2020-10-05 |
4 |
OE |
$7.37 |
$43,748 |
D/D |
5,936 |
5,936 |
|
- |
|
| Henderson John T |
Director |
– • – |
2020-10-05 |
4 |
AS |
$28.00 |
$87,000 |
D/D |
(3,000) |
899 |
|
-27% |
|
| Henderson John T |
Director |
– • – |
2020-10-05 |
4 |
OE |
$12.96 |
$38,880 |
D/D |
3,000 |
2,399 |
|
- |
|
| Jaw Ching |
SVP Finance & CFO |
• – – |
2020-10-05 |
4 |
AS |
$30.00 |
$825,000 |
D/D |
(27,500) |
73,300 |
|
-27% |
|
| Jaw Ching |
SVP Finance & CFO |
• – – |
2020-10-05 |
4 |
OE |
$7.14 |
$275,700 |
D/D |
27,500 |
88,300 |
|
- |
|
1112 Records found
|
|
Page 21 of 45 |
|
|
1.22 (2.31%) 
